Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H16FN3 |
| Molecular Weight | 293.3381 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(CCF)C1=CC2=CC=C(C=C2C=C1)C(C)=C(C#N)C#N
InChI
InChIKey=IAVCEBMLYVGBLA-UHFFFAOYSA-N
InChI=1S/C18H16FN3/c1-13(17(11-20)12-21)14-3-4-16-10-18(22(2)8-7-19)6-5-15(16)9-14/h3-6,9-10H,7-8H2,1-2H3
| Molecular Formula | C18H16FN3 |
| Molecular Weight | 293.3381 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. | 2001 Dec 15 |
|
| Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. | 2002 Jan-Feb |
|
| In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile. | 2003 |
|
| Molecular-imaging probe 2-(1-[6-[(2-fluoroethyl)(methyl) amino]-2-naphthyl]ethylidene) malononitrile labels prion plaques in vitro. | 2003 Sep 3 |
|
| The 2,6-disubstituted naphthalene derivative FDDNP labeling reliably predicts Congo red birefringence of protein deposits in brain sections of selected human neurodegenerative diseases. | 2006 Apr |
|
| PET of brain amyloid and tau in mild cognitive impairment. | 2006 Dec 21 |
|
| Seeing what Alzheimer saw. | 2007 Feb |
|
| High-yield, automated radiosynthesis of 2-(1-{6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile ([18F]FDDNP) ready for animal or human administration. | 2007 Jan-Feb |
|
| In vivo molecular imaging biomarkers: clinical pharmacology's new "PET"? | 2007 Jun |
|
| Getting a grip on Alzheimer's disease: imaging amyloid in the brain. | 2007 Mar |
|
| PET scanning in mild cognitive impairment. | 2007 Mar 15 |
|
| PET scanning in mild cognitive impairment. | 2007 Mar 15 |
|
| Synthesis of 2-(1,1-dicyanopropen-2-yl)-6-(2-[18F]-fluoroethyl)-methylamino-naphthalene ([18F]FDDNP). | 2008 Feb |
|
| Amyloid and tau imaging, neuronal losses and function in mild cognitive impairment. | 2008 Jan |
|
| Flurbiprofen derivatives in Alzheimer's disease: synthesis, pharmacokinetic and biological assessment of lipoamino acid prodrugs. | 2008 Jan |
|
| Amyloid imaging in aged and young macaques with [11C]PIB and [18F]FDDNP. | 2008 Jun |
|
| [In-vivo imaging of amyloid plaques]. | 2008 May |
|
| Peripheral metabolism of [(18)F]FDDNP and cerebral uptake of its labelled metabolites. | 2008 Nov |
|
| Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies. | 2009 Apr |
|
| Biomarkers of Alzheimer's disease. | 2009 Aug |
|
| Differential association of [11C]PIB and [18F]FDDNP binding with cognitive impairment. | 2009 Dec 15 |
|
| Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. | 2009 Feb |
|
| Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia. | 2009 Jan |
|
| Clinical applications of PET amyloid imaging: an update. | 2009 Jul |
|
| Dissecting molecular mechanisms in the living brain of dementia patients. | 2009 Jul 21 |
|
| Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. | 2009 Jul-Aug |
|
| Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults. | 2009 Jun |
|
| Differential FDDNP PET patterns in nondemented middle-aged and older adults. | 2009 May |
|
| Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. | 2009 Sep |
|
| Evaluation of tracer kinetic models for analysis of [18F]FDDNP studies. | 2009 Sep-Oct |
|
| Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG. | 2010 Aug 15 |
|
| 2-(1-{6-[(2-[fluorine-18]fluoroethyl)(methyl) amino]-2-naphthyl} ethylidene)malononitrile (FDDNP) positron emission tomography patterns in nondemented populations. | 2010 Feb |
|
| Movement correction method for human brain PET images: application to quantitative analysis of dynamic 18F-FDDNP scans. | 2010 Feb |
|
| FDDNP binding using MR derived cortical surface maps. | 2010 Jan 1 |
|
| Simplified parametric methods for [18F]FDDNP studies. | 2010 Jan 1 |
|
| Dementia mimicking Alzheimer's disease Owing to a tau mutation: CSF and PET findings. | 2010 Jul-Sep |
|
| Quantitative analysis of [18F]FDDNP PET using subcortical white matter as reference region. | 2010 Mar |
|
| PET of brain prion protein amyloid in Gerstmann-Sträussler-Scheinker disease. | 2010 Mar |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:00:59 UTC 2023
by
admin
on
Sat Dec 16 10:00:59 UTC 2023
|
| Record UNII |
9U8TYP0V3P
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9U8TYP0V3P
Created by
admin on Sat Dec 16 10:00:59 UTC 2023 , Edited by admin on Sat Dec 16 10:00:59 UTC 2023
|
PRIMARY | |||
|
590365-47-2
Created by
admin on Sat Dec 16 10:00:59 UTC 2023 , Edited by admin on Sat Dec 16 10:00:59 UTC 2023
|
PRIMARY | |||
|
24858429
Created by
admin on Sat Dec 16 10:00:59 UTC 2023 , Edited by admin on Sat Dec 16 10:00:59 UTC 2023
|
PRIMARY |